Clinical Trials
64 trialsNCT07218926 2026-05-27
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT06088290 2026-05-15
SaLuDo
PharmaMar
Phase 3 Active not recruiting
NCT07585266 2026-05-13
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07570823 2026-05-06
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sinocelltech Ltd.
Phase 3 Not yet recruiting
NCT05712694 2026-04-20
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group
Phase 3 Recruiting
NCT06935409 2026-04-09
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Hansoh BioMedical R&D Company
Phase 3 Active not recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT07174427 2026-02-18
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Takara Bio Inc.
Phase 3 Recruiting
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT06058793 2026-01-09
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 3 Completed
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
NCT03785964 2025-01-31
DeFi
SpringWorks Therapeutics, Inc.
Phase 3 Completed
NCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT06640361 2024-12-27
A Study of Olverembatinib in SDH-deficient GIST.
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT06370871 2024-07-17
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
Phase 3 Withdrawn
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT04650984 2024-04-08
FIBROSARC
Philogen S.p.A.
Phase 3 Unknown
NCT04409223 2024-02-09
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT01327885 2023-06-22
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Eisai Inc.
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
NCT03353753 2022-11-21
INVICTUS
Deciphera Pharmaceuticals, LLC
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT05121350 2022-02-18
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT02847429 2021-01-22
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Arog Pharmaceuticals, Inc.
Phase 3 Unknown
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT03520959 2020-04-16
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00099177 2017-08-16
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Hoffmann-La Roche
Phase 3 Terminated
NCT00099203 2017-08-16
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Hoffmann-La Roche
Phase 3 Terminated
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT02561039 2016-11-02
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
Hoffmann-La Roche
Phase 3 Completed
NCT01343277 2016-08-26
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT01440088 2016-06-02
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Threshold Pharmaceuticals
Phase 3 Completed
NCT02716792 2016-03-23
A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00699517 2015-12-21
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
Sanofi
Phase 3 Completed
NCT00796120 2015-12-10
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00038311 2015-05-04
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Pfizer
Phase 3 Completed
NCT00538239 2015-02-13
SUCCEED
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed